文献速递肝病消化道肿瘤与早癌

无干扰素直接抗病毒药物治疗慢性丙型肝炎不改变肝硬化患者短期新发肝细胞癌风险

Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-04

该研究前瞻性监测373例接受无干扰素直接抗病毒药物治疗的慢性丙型肝炎患者,并从2007至2013年随访的3715例丙型肝炎患者中回顾性招募未治疗肝硬化对照。158例治疗组与184例对照组肝硬化患者纳入分析,中位随访分别为440天和592天,肝细胞癌发生率分别为2.90 vs 4.48例/100人年。结论认为无干扰素直接抗病毒药物治疗不改变肝硬化患者短期肝细胞癌风险,随访超过1.5年后肝细胞癌发生率降低可能变得明显。

要点

  • 直接抗病毒药物治疗组与未治疗对照组肝细胞癌发生率分别为2.90 vs 4.48例/100人年。
  • 治疗组在开始治疗后450天以后无新发肝细胞癌病例。
  • 多因素分析显示较高MELD评分和甲胎蛋白水平与肝细胞癌发生独立相关。

核心结论

  • 无干扰素直接抗病毒药物治疗慢性丙型肝炎不改变肝硬化患者短期肝细胞癌风险,随访超过1.5年后肝细胞癌发生率降低可能变得明显。

研究设计与样本

  • 前瞻性监测2014年1月后接受无干扰素直接抗病毒药物治疗的373例慢性丙型肝炎患者,并从2007至2013年在本中心随访的3715例丙型肝炎患者中回顾性招募未治疗肝硬化对照,采用相似的肝细胞癌筛查方案。
  • 158例直接抗病毒药物治疗组和184例对照组肝硬化患者纳入分析。

主要发现

  • 两组在性别、基因型分布、肝病严重程度和糖尿病患病率方面无差异。
  • 患者中位随访分别为440天(范围91-908天)和592天(范围90-1000天)。
  • 随访期间分别有6例和14例发生肝细胞癌,发生率分别为2.90 vs 4.48例/100人年。
  • 直接抗病毒药物治疗组在开始治疗后450天以后无新发肝细胞癌病例。
  • 多因素分析显示较高MELD评分和甲胎蛋白水平与肝细胞癌发生独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) clearance with IFN-based therapies reduces the incidence of hepatocellular carcinoma (HCC). There has been some debate if IFN-free therapy with direct-acting antivirals alters the risk for HCC. AIM: To investigate the HCC incidence in cirrhotic HCV patients who cleared HCV with direct-acting antivirals vs untreated controls. METHODS: We prospectively monitored 373 patients with chronic hepatitis C who received IFN-free therapies with direct-acting antiviral after January 2014. A retrospective control cohort of untreated cirrhotic patients was recruited out of 3715 HCV patients who were followed at our centre between 2007 and 2013, with similar HCC screening protocols. RESULTS: 158 direct-acting antiviral-treated and 184 control patients with liver cirrhosis were included in this analysis. The groups did not differ in gender and genotype distribution, severity of liver disease and prevalence of diabetes mellitus. Patients were followed up for a median of 440 (range 91-908) and 592 (range 90-1000) days. HCCs developed in 6 and 14 patients during follow-up, resulting in an incidence of 2.90 vs 4.48 HCCs per 100 person-years. In the direct-acting antiviral-treated group, there was no new case of HCC later than 450 days after treatment initiation. In multivariate analysis, higher MELD-Scores and AFP-levels were independently associated with HCC development. Transplant-free patient survival was similar in both groups. CONCLUSIONS: IFN-free direct-acting antiviral therapy of chronic hepatitis C does not alter the short-term risk for HCC in patients with liver cirrhosis. A reduced HCC incidence may become evident after more than 1.5 years of follow-up.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 2017. PMID: 29205405. doi:10.1111/apt.14427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。